Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

An Open Label Study to Evaluate the Safety of Dasatinib in the Treatment of Scleroderma Pulmonary Interstitial Fibrosis

NCT00764309 is registered in ClinicalTrials.gov with Bristol-Myers Squibb as lead sponsor.

NCT NCT00764309
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT00764309 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
An Open Label Study to Evaluate the Safety of Dasatinib in the Treatment of Scleroderma Pulmonary Interstitial Fibrosis
Lead sponsor
Bristol-Myers Squibb
Phase
Phase 1/2
Overall status
Completed
Start date
January 31, 2009
Completion date
April 30, 2011
Enrollment
47 (actual)
Sites
13

Conditions

As the registry lists them; a condition with its own page is linked.

scleroderma